GrechLBButlerEStuckeyS, et al. Letter to the editor: FLOUX-PMS study sample considerations. Mult Scler2019; 25: 1819–1820.
2.
CambronMMostertJD’HoogheM, et al. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial. Mult Scler2019; 25: 1728–1735.
3.
KochMUyttenboogaartMvan HartenA, et al. Fatigue, depression and progression in multiple sclerosis. Mult Scler2008; 14: 815–822.
4.
ChatawayJWeirCJFoxRJ.The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials. Mult Scler2019; 25: 1697–1699.
5.
MostertJPAdmiraal-BehloulFHoogduinJM, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: A double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry2008; 79(9): 1027–1031.
6.
FoleyPLawlerAChandranS, et al. Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry2014; 85(6): 709–710.
